Table 3.
Clinicopathological characteristics of cytotoxic molecule‐positive, Epstein–Barr virus‐negative cutaneous T‐cell lymphoma, unspecified
| Characteristic | n | % |
|---|---|---|
| Total | 27 | |
| Sex (male/female) | 18/9 | |
| Age (years), median (range) | 49 (25–87) | |
| Performance status score 2–4 | 2 | 7 |
| Clinical stages higher than 2 | 4 | 15 |
| B symptoms | 7 | 26 |
| Case limited to the skin | 19 | 70 |
| Lymph node involvement | 7 | 26 |
| Bone marrow involvement | 1 | 4 |
| LDH higher than normal | 8 | 30 |
| International Prognostic Index, HI/H | 3 | 11 |
| Prognostic Index for Peripheral T‐cell Lymphoma group 3–4 | 6 | 22 |
| Gross appearance | ||
| Nodule | 18 | 67 |
| Multiple nodules | 16 | 59 |
| Spontaneous regression | 7 | 26 |
| Fatal course within 1 year of diagnosis | 5 | 19 |
| Death | 8 | 30 |
| Histology | ||
| Subcutaneous involvement | 22 | 81 |
| Immunophenotype | ||
| CD2 | 25 | 93 |
| cyCD3 | 23/26 † | 88 |
| CD4 | 14 | 52 |
| CD5 | 14/26 † | 54 |
| CD7 | 9 | 33 |
| CD8 | 9 | 33 |
| CD20 | 0 | 0 |
| CD25 | 17/25 † | 68 |
| CD30 | 17 | 63 |
| CD45RO | 21 | 78 |
| CD56 | 5 | 19 |
| TCR‐β | 13 | 48 |
| EBER | 0 | 0 |
| CCR4 | 0 | 0 |
| CXCR3 | 27 | 100 |
| FOXP3 | 0/25 † | 0 |
| T‐cell intracellular antigen‐1 | 22 | 81 |
| Granzyme B | 25 | 93 |
| Perforin | 19/25 † | 76 |
| Polymerase chain reaction | ||
| TCR gene rearrangements | 4/24 † | 17 |
EBER, Epstein‐Barr virus encoded small RNA; HI/H, high to intermediate risk/high risk; LDH, lectate dehydrogenase; TCR, T‐cell receptor.
†
The denominator represents the number of cases examined.